ãç½èå 人å湯ãã¯ãæ¼¢æ¹ã®å¤å ¸ã¨ããããä¸å½ã®å»æ¸ãå·å¯è«ï¼»ã·ã§ã¦ã«ã³ãã³ï¼½ããéå±è¦ç¥ï¼»ãã³ãã¨ã¦ãªã£ã¯ï¼½ãã«åè¼ããã¦ããè¬æ¹ã§ãã å¥åãç³èç¥æ¯å 人å湯
ãç½èå 人å湯ãã¯ãæ¼¢æ¹ã®å¤å ¸ã¨ããããä¸å½ã®å»æ¸ãå·å¯è«ï¼»ã·ã§ã¦ã«ã³ãã³ï¼½ããéå±è¦ç¥ï¼»ãã³ãã¨ã¦ãªã£ã¯ï¼½ãã«åè¼ããã¦ããè¬æ¹ã§ãã å¥åãç³èç¥æ¯å 人å湯
Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Aspergerâs disorder: a 12-week prospective, open-label study Research article Open access Published: 29 November 2012 Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Aspergerâs disorder: a 12-week prospective, open-label study Tsuyoshi Miyaoka1, Rei Wake
1962å¹´ 大éªå¤§å¦ãè¬å¦å士ãå¦ä½è«æã¯ãéåã»çé é¡ã®çè¬å¦çç 究ã[1]ã å¯å±±å»ç§è¬ç§å¤§å¦åèªææ ä¸å½è¬ç§å¤§å¦ï¼å京ï¼åèªææ çé½è¬å¦é¢å®¢åº§ææ åæçä¸å»ä¸è¬ç 究é¢åèªç ç©¶å¡ å京ä¸å»å¦é¢åèªææ æé½ä¸å»å¦é¢åèªææ æ¹åä¸å»å¦é¢ï¼æ¦æ¼¢ï¼åèªææ å京å»ç§å¤§å¦å®¢åº§ææ åå·çä¸è¬ç 究æï¼éæ ¶ï¼å®¢åº§ç 究å¡
ï¼æ°æè¬ç©ãã¼ã¿ãã¼ã¹ã«ã¯ãæ°æè¬ç©è³æ館ã«ä¿ç®¡ããã¦ããçè¬ã®æ¨æ¬æ å ±åã³ å¦è¡æ å ±ãåé²ããã¦ãã¾ãã ï¼ãã®ãã¼ã¿ãã¼ã¹ã®ä¸é¨ã¯ï¼æ¥æ¬å¦è¡æ¯èä¼ç§å¦ç 究費è£å©éãç 究ææå ¬éä¿é²è²»ã ï¼å¹³æ11年度-13年度ï¼ã«ããä½æããããã®ã§ãã ï¼ã¦ããã¼çè¬åã³ã¿ã¤çè¬ãã¼ã¿ãã¼ã¹ã®æ å ±ã¯è±èªè¡¨è¨ã§ãã
ç¾å¨ããã ã©ã¯è¨åå·¥å ´ã®éç½è¢«å®³ã®ãããæ±ç¨ãããæ¼¢æ¹è¬ã®ä¾çµ¦ã«å½±é¿ãåºã¦ããããã§ããããã ã©ã®ãã¼ã ãã¼ã¸ã§ã¯ãã2011å¹´5æä¸æ¬ã«ã¯å ¨è£½é å·¥ç¨ã«ããã¦ææ¥ãåéãããã¨è¨è¼ããã¦ããã6æã«ã¯ä¾çµ¦ä½å¶ãæ´ãè¦è¾¼ã¿ããããç¾å¨ã®ã¨ãããç¾å ´ã§ã¯é·æå¦æ¹ãé¿ãããã¨ã§å¯¾å¿ãã¦ããã æ¼¢æ¹ã¯ããªãã®ç¨®é¡ãããããå¤ãå¦æ¹ãããæ¼¢æ¹ã¯ãã»ã©ã®å°éå»ã§ãªãéãéããã¦ãããæ®æ®µå¦æ¹ãããªãæ¼¢æ¹è¬ã¯ä»ã§ãååãªå¨åº«ãããã¨æããããï¼6æã¾ã§ãªãã°ï¼ã 以ä¸ãæ±ç¨ãããæ¼¢æ¹ã§ä¸è¶³ããéã代æ¿å¯è½ãªæ¼¢æ¹ã®ç´¹ä»ã§ããã証ãå¾®å¦ã«ç°ãªã飲ã¿å¿å°ãå¤ãã£ãããæå¾ ããå¹æããªããã¨ããããããããªãã â ãã ã©ï¼ï¼èæ ¹æ¹¯ï¼ æåã®å®çªã¨ãããæ¼¢æ¹è¬ãè©çã«ãè¯ãããã 漫ç¶ã¨æä¸ããã¨é»è§£è³ªç°å¸¸ãçãããã¨ãããã ãã ã©127ï¼éº»é»éåç´°è¾æ¹¯ï¼ã¾ãã¯ãã ã©45ï¼æ¡ææ¹¯ï¼ ãããã¯ããã ã©127ã¨ãã ã©
å å³å¸°è¾æ¹¯ã£ã¦ã©ããªè¬ã§ããï¼ å å³å¸°è¾æ¹¯ã¯ããæ¸çå ¨æ¸ã(1529) ãåå ¸ã¨ããæ¼¢æ¹è¬ã§ãã ä¸å½ãæ¥æ¬ã§ã¯ãèè ¸ã®èå¼±ãªäººã«ç²¾ç¥çãªéå´ãå ãããå¿èº«ã¨ãã«ç²å´ã®æ¥µã«éããç²¾ç¥ä¸å®ã ä¸ç ãç¥çµçã貧è¡ã®äººã«ä½¿ããã¦ãã¾ããç¥çµç¾æ£ã§ã¯ãå¥å¿çãä¸ç çãç¥çµæ§å¿æ¸äº¢é²ã ãã¹ããªã¼ãç¥çµè¡°å¼±ãªã©ã®æ²»çã«ä½¿ããã¦ãã¾ãã è¬å¤ã®æ¯è¼ å å³å¸°è¾æ¹¯ã®ããã±ã¼ã¸è£½å¤ã¯ã«ããã¦ããã ã©ã太èç²¾å ãªã©ã®ä¼ç¤¾ã§ä½ããã¦ãã¾ãã 7.5gä¸ã«14ãã15種é¡ã®çè¬æåï¼ã«ããã¦ï¼5600mgããã ã©ï¼5000mgã太èç²¾å ï¼5180mgï¼ã 以ä¸ã®å²åã§å«ã¾ãã¦ãã¾ãã ã«ããã¦ãããã ã©ãã太èç²¾å é»è
ãä½åº¦ããã¤ã¬ã«èµ·ããã®ã¯å¹´ã®ã⦠æ£è ãçããä½åº¦ãå°¿æã§ç®ãè¦ãããä¸æ©ã«ï¼åãå¹´ã®ããï¼ã(2019/8/19) â æ£è ãçããã»ç ããå¤éé »å°¿ãï¼ï¼ï¼ ãªããå¤ä¸ã«ä½åº¦ããã¤ã¬ã«è¡ããããªãã®ã ããââã 京é½å¸ã®å¾³ç°ç¾ä¿ï¼ã¨ãã ã¿ã»ï¼ããï¼ï¼ï¼ï¼â¦[ç¶ããèªã] ææçãåå ã®ããã¯ãææã®äºé²ã»æ²»çã§é²ãã¾ã[å ç§å»ã»é äºå¥å¸ã®å»å¿é»ä¿¡](2019/8/19) æ°åºçå診æãèªå®å¤æ½è¨ã§åºãããä¸ç¢ºå®ãªã¾ã¾ä¸çµ¶ã[ãã¥ã¼ã¹ã»ãã©ã¼ã«ã¹](2019/8/16)  ãæ²»ããèªç¥çãã®æè¡ãè² æ å°ãªãææ³ããããåºãã[ãã¥ã¼ã¹ã»ãã©ã¼ã«ã¹](2019/8/14)  æ¶è²»ç¨åï¼ï¼ï¼ååãå½ç«å¤§ç é¢ãè² æ ãçµå¶ãå§è¿«[ãã¥ã¼ã¹ã»ãã©ã¼ã«ã¹](2019/8/19)  å»å¤§ç é¢äºå®å°ã¯ãµã¼ã«ã¹ä¼å ´ãã©ããªãå¼çã®å»å¸«ä¸è¶³[ãã¥ã¼ã¹ã»ãã©ã¼ã«ã¹](2019/8/19) æ©ãã¦ãã¤ã³ã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}